Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Guidelines
Pharmacology

British journal of clinical pharmacology

Points to consider on switching between superiority and non-inferiority

2001National

United Kingdom

Read the PDF Original at the sourceAsk Osler about this guideline

On this page

Read the guideline
Source and rights

Read the guideline

Full guideline, as published161 KBOpen in a new tab Download

Source and rights

Published by British journal of clinical pharmacology, 2001. The PDF is shown as published and remains the work of its authors and publisher; the original is at the source linked here. Rights holders can ask us to remove a file at info@prognia.nl.

pmc.ncbi.nlm.nih.gov/articles/PMC2014556/

More in pharmacology

Building a HBCU/PBI Pharmacy Collaborative as an Approach to Sharing Successful Practices and ResourcesAmerican journal of pharmaceutical education · 2026Added 18 Jul 2026PDF
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)British journal of clinical pharmacology · 2026

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Published: 2001
Applies to: 🇬🇧 United Kingdom
Scope: National
Journal: British journal of clinical pharmacology
DOI: 10.1046/j.0306-5251.2001.01397-3.x
PubMed: 11560553
PubMed Central: PMC2014556
Added to Prognia: 25 July 2026

Added 18 Jul 2026PDF

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 UpdateClinical pharmacology and therapeutics · 2026Added 17 Jul 2026PDF

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 UpdateClinical pharmacology and therapeutics · 2026Added 16 Jul 2026PDF

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)British journal of clinical pharmacology · 2026Added 16 Jul 2026PDF

ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)British journal of clinical pharmacology · 2026Added 16 Jul 2026PDF

pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic CancerPancreas · 2026Added 16 Jul 2026

AAC 20262025-2026 Academic Affairs Committee Report: Advancing Competency-Based Pharmacy Education and Academic CoachingAcademic Affairs Committee · 2026Added 16 Jul 2026

AACP 2025Building Implementation Science Capacity in Academic Pharmacy: Report of the 2020-2021 AACP Research and Graduate Affairs CommitteeAmerican Association of Colleges of Pharmacy · 2025Added 18 Jul 2026PDF

CPIC 2025Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyClinical Pharmacogenetics Implementation Consortium · 2025Added 18 Jul 2026PDF

Approaches for Embedding Structural Competency and Social Determinants of Health in Pharmacy CurriculaAmerican journal of pharmaceutical education · 2025Added 22 Jul 2026

To Stay or To Go? Debate Regarding US News and World Report Pharmacy Program RankingsAmerican journal of pharmaceutical education · 2025Added 18 Jul 2026